To investigate the clinical efficacy and safety of somatostatin injection combined with ulinastatin injection in patients with severe acute pancreatitis (SAP).

Patients with SAP were divided into control group and experimental group by random number table method. Both groups received routine basic treatment. On this basis, the control group was additionally given somatostatin injection (6 mg once daily). The experimental group was treated with ulinastatin injection by intravenous infusion at a dose of 100 000 units three times a day on the basis of the control group. Both groups continued to receive treatment for 7 days. Compare the clinical efficacy, inflammatory factor levels, symptom relief time, intestinal mucosal function [D-lactate, diamine oxidase (DAO), and Endotoxin] of the two groups, and conduct a safety evaluation.

A total of 160 patients were enrolled in this study, both the treatment group and the control group included 80 cases. The total effective rates in the treatment group and the control group were 91.25% (73 cases/80 cases) and 75.00% (60 cases/80 cases), respectively, with statistically significant difference (P<0.05). After treatment, the levels of tumor necrosis factor-α (TNF-α) in the treatment group and the control group were (22.46±5.90) and (28.85±6.37) pg·L^-1, respectively; the levels of interleukin-6 (IL-6) were (92.03±20.22) and (122.78±27.59) pg·L^-1, respectively; the levels of Presepsin were (1.25±0.54) and (1.55±0.58) μg·L^-1, respectively; the levels of D-lactate were (5.31±0.75) and (8.19±0.93) mg·L^-1, respectively; the levels of DAO were (4.29±0.88) and (9.84±1.05) U·L^-1, respectively; the levels of endotoxin were (0.63±0.18) and (1.21±0.25) EU·L^-1, respectively; the duration of abdominal pain relief was (3.14±0.42) and (4.98±0.51) d, respectively; the time for amylase to return to normal was (4.32±0.46) and (5.37±0.56) d, respectively. All these differences of the aforementioned indicators were statistically significant in both groups (P<0.05). The incidence of adverse drug reactions during treatment in the control group and the treatment group was 6.25% (5 cases/80 cases) and 6.25% (5 cases/80 cases), respectively, and the incidence of complications was 3.75% (3 cases/80 cases) and 2.50% (2 cases/80 cases), respectively. There were no statistical differences between the two groups (P>0.05).

Ulinastatin combined with somatostatin in the treatment of SAP patients can effectively reduce the levels of inflammatory factors, alleviate inflammatory response, promote the recovery of intestinal mucosal function, and has better curative effect, without increasing the occurrence of adverse reactions, with certain safety and effectiveness.